Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

BACKGROUND: Fibroblast growth factor receptor 2 (FGFR2) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer (BTC). However, efficient detection and the exact frequency of FGFR2 rearrangements among patients with advanced/recurrent BTC have not been d...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruki, Yuta, Morizane, Chigusa, Arai, Yasuhito, Ikeda, Masafumi, Ueno, Makoto, Ioka, Tatsuya, Naganuma, Atsushi, Furukawa, Masayuki, Mizuno, Nobumasa, Uwagawa, Tadashi, Takahara, Naminatsu, Kanai, Masashi, Asagi, Akinori, Shimizu, Satoshi, Miyamoto, Atsushi, Yukisawa, Seigo, Kadokura, Makoto, Kojima, Yasushi, Furuse, Junji, Nakajima, Takako Eguchi, Sudo, Kentaro, Kobayashi, Noritoshi, Hama, Natsuko, Yamanaka, Takeharu, Shibata, Tatsuhiro, Okusaka, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932978/
https://www.ncbi.nlm.nih.gov/pubmed/33106918
http://dx.doi.org/10.1007/s00535-020-01735-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932978/
https://www.ncbi.nlm.nih.gov/pubmed/33106918
http://dx.doi.org/10.1007/s00535-020-01735-2

Ejemplares similares